NSE: SBILIFE· InsuranceCore · Aug 26Large cap
SBI Life Insurance Company
Lowest-cost, highest-persistency
- Last close
- ₹1,735.00
- 29 Sept 2026 · reference
- 1D · 1M
- +0.4% · −1.5%
- price-only
- Weight
- 1.1%
- 31 Jul 2026 · Aug rank 26
- Thesis review
- 8 Sep 2026
- Why We Own, p38
Where the price sits
52-week range, house target and street targets
52w low ₹1,65452w high ₹2,110
- Reference close₹1,735
- Antique Stock Broking Limited · BUY₹2,400
- YES Securities · BUY₹2,350
Range from reference closes; street targets from the PDFs on file (Research & documents). Internal target is never shown to prospects.
Investment case and valuation
Approved model, 8 Sep 2026 review
₹1,732
Price (2026-09-07)
70.5x / 57.9x
FY27E / FY28E P/E (Buoyant sheet)
14.6%
FY27E ROE (Buoyant sheet)
66.8x
Trailing P/E
8.6x
Price / book
23%
EPS CAGR FY26–28E
At Rs 1,732 the stock is ~2.0x trailing EV (Rs 85,290 cr, Jun-2026) and 1.8x/1.5x FY27E/FY28E P/EV (Nuvama) vs HDFC Life at 1.6x/1.4x - a ~0.2x premium for 20%+ APE growth vs HDFC Life's 17%; Axis Direct trimmed its target multiple to 2.1x from 2.2x FY28E EV. Own 5y average P/EV not sourced. EV/EBITDA n.m.; dividend yield 0.2%.
- Model date
- 8 Sep 2026 (prices 7–8 Sep 2026)
- Horizon
- 12 months (bank pages: Sep-2027 roll-forward)
- Audience
- Internal — the book's guardrail: do not quote a target to a client; quote the thesis and the risk
- Reviewer · version
- Investment Committee framework · v1 (book)
Current vs history
Trailing multiples, FY-end
| Ratio | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to Book | n.m. | 10.6x | 7.8x | 7.2x | 8.7x | 9.8x | 8.5x | 10.3x | 9.2x | 9.4x |
Tijori FY-end multiples on reported earnings/book; compatible definitions across years, but not the same basis as Buoyant's forward P/E on internal EPS.
UnavailableScenario lab disabled. Needs an approved forward EPS and forward P/E for SBI Life Insurance Company plus a reference price. Missing inputs are not substituted.